Annual change in FIB-4, but not in APRI, was a strong predictor for liver disease progression in Chinese patients with chronic hepatitis C

0Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Background: Previous studies showed a significant prognostic value of 3-year and 5-year evolution of noninvasive fibrosis tests in European chronic hepatitis C (CHC) patients with or without HIV. It is uncertain whether this conclusion can be extrapolated to Chinese patients and whether the assessment of noninvasive fibrosis tests in a shorter time interval still has a prognostic value. Objectives: The study aimed to assess the prognostic value of changes of aspartate aminotransferase-to-platelet ratio (APRI) and fibrosis-4 (FIB-4) in consecutive years in Chinese CHC patients. Methods: There were 173 CHC patients enrolled in 2 centers in this retrospective study. APRI and FIB-4 were calculated every 12 ≤ 2 months. The average difference between 2 adjacent calculations was defined as an annual change (AC). Risk factors were evaluated by Cox proportional regression models. Results: Cirrhosis, hepatic decompensation, hepatocellular carcinoma, and liver-related death developed in 29 patients during the median follow-up of 47.0 (29.5 - 72.0) months. Baseline FIB-4 and APRI, Child-Pugh class C, non-sustained virologic response (SVR) to interferon (IFN) or Pegylated IFN plus ribavirin, and AC of FIB-4 were significantly associated with liver disease progression. AC of FIB-4 (P < 0.001) exhibited a more robust prognostic value than AC of APRI (P = 0.228). Excellent prognosis was observed in patients with AC of FIB-4 ≤ 0.22 and baseline FIB-4 ≤ 3.25, or AC of FIB-4 ≤ 0.22 and SVR. Patients with baseline FIB-4 > 3.25 and AC of FIB-4 > 0.22, or non-SVR and AC of FIB-4 > 0.22 had the highest cumulative incidence of liver disease progression among the 4 groups identified according to baseline FIB-4 and AC of FIB-4, or SVR and AC of FIB-4. Conclusions: An increased FIB-4 over time is an independent risk factor of liver disease development in Chinese CHC patients. Monitoring FIB-4 annually may help physicians to predict prognosis in CHC patients.

Cite

CITATION STYLE

APA

Xiao, L., Wang, W., Xian, J., Zhang, W., Li, Y., Yang, X., & Lu, L. (2018). Annual change in FIB-4, but not in APRI, was a strong predictor for liver disease progression in Chinese patients with chronic hepatitis C. Hepatitis Monthly, 18(3). https://doi.org/10.5812/hepatmon.57250

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free